Johnson & Johnson (JNJ)

128.33
0.31 0.24
NYSE : Health Technology
Prev Close 128.64
Open 128.61
Day Low/High 128.16 / 129.45
52 Wk Low/High 121.00 / 148.99
Volume 1.86M
Avg Volume 6.85M
Exchange NYSE
Shares Outstanding 2.66B
Market Cap 345.98B
EPS 5.70
P/E Ratio 24.13
Div & Yield 3.80 (2.76%)

Checking in on Every Portfolio Name: Where Would We Buy?

We are providing buy price levels for nearly every position in the AAP portfolio.

Weekly Roundup

Markets pull back as earnings season gets underway.

Go for the Easy Money: Cramer's 'Mad Money' Recap (Thursday 7/18/19)

Go for the Easy Money: Cramer's 'Mad Money' Recap (Thursday 7/18/19)

Jim Cramer says Netflix just went from being an easy-money stock to a hard-money stock. Investors need to know the difference.

Jim Cramer: Looking for Netflix Action? Don't Be a Hero

Jim Cramer: Looking for Netflix Action? Don't Be a Hero

Stranger things have happened, but with NFLX's subscriber miss, the stock just became hard money, joining the likes of Johnson & Johnson and CSX Corp.

Small Caps Rise as Traders Change Channel on NFLX, Other Big Caps

Small Caps Rise as Traders Change Channel on NFLX, Other Big Caps

It's a stock picker's market as action in individual stocks is better than on the indexes.

Complacent Market Players Keep It Chill -- as Sparks Fly All 'Round

Complacent Market Players Keep It Chill -- as Sparks Fly All 'Round

It is still a surprisingly sedate market, despite indexes sitting close to all-time highs, earnings season, possible interest-rate cuts and endless speculation about China trade.

Dow Ends Lower; Stocks Slip as Trump Fans China Trade Worries

Dow Ends Lower; Stocks Slip as Trump Fans China Trade Worries

The Dow ends down after reaching an intraday day Tuesday as President Trump says the U.S. and China have `a long way to go' before reaching a trade agreement.

Johnson & Johnson Beats With Second Quarter Results

We think JNJ's valuation is still cheap as it has a below market multiple despite consistent earnings growth.

Video: Jim's Daily Rundown for Tuesday

Jim shares his thoughts on earnings from JPMorgan Chase, Goldman Sachs and Johnson & Johnson.

See How Johnson & Johnson Ranks Among Analysts' Top Dow 30 Picks

See How Johnson & Johnson Ranks Among Analysts' Top Dow 30 Picks

A study of analyst recommendations at the major brokerages shows that Johnson & Johnson is the #18 broker pick, on average, out of the 30 stocks making up the Dow Jones Industrial Average, according to ETF Channel. Within the broader S&P 500, when components were ranked in terms of analyst favorites, JNJ claims the #263 spot.

Johnson & Johnson Tops Q2 Earnings Estimate, Boosts 2019 Sales Forecast

Johnson & Johnson Tops Q2 Earnings Estimate, Boosts 2019 Sales Forecast

Johnson & Johnson posted stronger-than-expected second quarter earnings Tuesday and boosted its full-year sales outlook as international pharmaceutical revenues offset a domestic pullback.

Markets' Health, Facebook Libra Hearings, Trading Match Group: Market Recon

Markets' Health, Facebook Libra Hearings, Trading Match Group: Market Recon

For those trading the FANG or FAANG names, and especially Facebook, Tuesday sets up as a day bearing exceptional levels of headline risk.

This Sedate Market Is an Ink Blot Test for Investors

This Sedate Market Is an Ink Blot Test for Investors

The bulls will say this is healthy consolidation that will set up another leg higher, while the bears will say this is an indication of indecision and is a prelude to a rollover.

Johnson & Johnson Reports 2019 Second-Quarter Results

Johnson & Johnson Reports 2019 Second-Quarter Results

- Sales of $20.6 billion reflecting a decline of 1.3%, operational growth of 1.6%* and adjusted operational growth of 3.7%*

Jim Cramer: Don't Play Earnings Season, Invest in It

Jim Cramer: Don't Play Earnings Season, Invest in It

Here are my five rules for handling earnings season.

J&J Reports Earnings Under a Cloud of Baby Powder

J&J Reports Earnings Under a Cloud of Baby Powder

Buy Johnson & Johnson at its monthly and quarterly pivots at $134.76 and $135.44. These levels have been magnets following Friday's share price plunge on baby powder probe.

Why Jim Cramer Says a Bad Set of Earnings Won't Drag Down the Markets

Why Jim Cramer Says a Bad Set of Earnings Won't Drag Down the Markets

Here's what Jim Cramer is watching in the markets as Wall Street heads into another earnings season.

Video: Jim's Daily Rundown for Monday

Jim discusses the market set up into second quarter earnings, Citigroup's earnings release from this morning, and much more!

Johnson & Johnson Announces Quarterly Dividend For Third Quarter 2019

Johnson & Johnson Announces Quarterly Dividend For Third Quarter 2019

NEW BRUNSWICK, N.J.

Teva Shares Slump on Opioid Litigation Risk Downgrade From Morgan Stanley

Teva Shares Slump on Opioid Litigation Risk Downgrade From Morgan Stanley

Shares of Teva Pharmaceuticals fall after the company receives a downgrade from Morgan Stanley amid heightened "litigation risks" related to its involvement in the opioid crisis.

Weekly Roundup

Markets surge to new records as Fed Chairman Jerome Powell signals rate cuts are likely.

J&J Stock Sinks as Feds Probe Baby Powder Cancer Allegations

J&J Stock Sinks as Feds Probe Baby Powder Cancer Allegations

News of a federal probe into whether J&J intentionally misled the public over the safety of its iconic baby powder overshadows the pharma giant's announcement of a potential HIV vaccine breakthrough.

Next Week's Earnings Previews

Here are 6 companies we'll be following.

Video: Jim's Daily Rundown for Friday

Jim discusses Nvidia and the opportunity it has with ray-tracing technology, Apple, our healthcare stocks, and much more!

J&J and Microsoft Among Defensive Stocks With Positive Earnings Outlooks

J&J and Microsoft Among Defensive Stocks With Positive Earnings Outlooks

Earnings season is about to start, and the early outlook isn't good. However, there are companies out there with good prospects and we take a look at three of them.

Weekly Roundup

Markets set records in holiday-shortened week.

Stocks End Lower; Jobs Rebound Trims Hope of Fed Rate Cut

Stocks End Lower; Jobs Rebound Trims Hope of Fed Rate Cut

Stocks fell Friday as a surprising rebound in June hiring reduced the likelihood of an interest rate cut by the Federal Reserve.

Johnson & Johnson: Key Points to Watch on the Charts

Johnson & Johnson: Key Points to Watch on the Charts

The stock has been bouncing off the 200-day moving average line.

Weekly Roundup

Markets are treading water as investors ponder the G-20, politics and stress tests.

TheStreet Quant Rating: B (Buy)